Literature DB >> 16738853

What patients take without telling you: holistic approach for BPH.

Jillian L Capodice1, Aaron E Katz.   

Abstract

The use of botanicals and supplements have markedly increased in men that are seeking increased protection against the potential onset and symptomatic relief of lower urinary tract symptoms that are commonly experienced with benign prostatic hyperplasia (BPH). While this implies a positive trend and considers that men are taking a more active role in health and prevention, dialog between the patient and the clinician is often deficient. This may be due to a number of factors including both the patients' inability to report about the use of certain agents and the clinicians' inability to ask. Moreover, the sense that natural agents may lack side effects coupled with ineffective communication between the doctor and patient could result in potential adverse interactions. We have performed a comprehensive search of articles published from 1990 to 2005 using the Medline databases in order examine clinical data on the most commonly researched herbs for BPH. We provide a brief update on the state of the research.

Entities:  

Mesh:

Year:  2006        PMID: 16738853     DOI: 10.1007/s00345-006-0093-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  42 in total

1.  Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.

Authors:  Frans Debruyne; Peter Boyle; Fernando Calais Da Silva; Jay G Gillenwater; Freddie C Hamdy; Paul Perrin; Pierre Teillac; Remigio Vela-Navarrete; Jean-Pierre Raynaud; Claude C Schulman
Journal:  Eur Urol       Date:  2004-06       Impact factor: 20.096

2.  Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.

Authors:  Fouad K Habib; Margaret Ross; Clement K H Ho; Valerie Lyons; Karen Chapman
Journal:  Int J Cancer       Date:  2005-03-20       Impact factor: 7.396

3.  Anti-androgenic activities of Ganoderma lucidum.

Authors:  Rumi Fujita; Jie Liu; Kuniyoshi Shimizu; Fumiko Konishi; Kiyoshi Noda; Shoichiro Kumamoto; Chie Ueda; Hisatoshi Tajiri; Shuhei Kaneko; Yoshitaro Suimi; Ryuichiro Kondo
Journal:  J Ethnopharmacol       Date:  2005-10-31       Impact factor: 4.360

Review 4.  Benign prostatic hyperplasia treated with saw palmetto: a literature search and an experimental case study.

Authors:  J M McPartland; P L Pruitt
Journal:  J Am Osteopath Assoc       Date:  2000-02

Review 5.  beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.

Authors:  T J Wilt; R MacDonald; A Ishani
Journal:  BJU Int       Date:  1999-06       Impact factor: 5.588

Review 6.  Pygeum africanum for benign prostatic hyperplasia.

Authors:  T Wilt; A Ishani; R Mac Donald; I Rutks; G Stark
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  Chemoprevention of prostate cancer.

Authors:  Eric A Klein
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

8.  Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia.

Authors:  Remigio Vela-Navarrete; Marta Escribano-Burgos; Antonio López Farré; Juan García-Cardoso; Felix Manzarbeitia; Carolina Carrasco
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

9.  Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.

Authors:  R R Berges; J Windeler; H J Trampisch; T Senge
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

Review 10.  Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.

Authors:  A C Buck
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.